Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1430)	7/22/1998 6:20:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 2173

Rudy, thanks for posting the link to the registration statement. It looks like all the right answers: <<The Common Stock is being offered, on an all or none basis, by the Company principally to selected institutional and individual investors. Though the exact investors to whom shares will be offered have not been identified, the Company expects the pool of such investors to include current holders of the Company's Common Stock and other institutional investors who purchase biotechnology stocks for longer-term investment purposes. ... The net proceeds to the Company from the sale of the 3,000,000 shares of Common Stock offered by the Company hereby are estimated to be $10.5 million, assuming a public offering price of $3.625 per share and after deducting the estimated offering expenses payable by the Company">> Enough money to get the company through the European PIII data with time to close out a corporate partnering deal if the data are good, but with as little dilution as possible at these prices. Plus shares will be placed in the right hands, probably primarily existing institutional and individual investors. Peter